155 related articles for article (PubMed ID: 34424582)
1. BEX2 is required for maintaining dormant cancer stem cell in hepatocellular carcinoma.
Fukushi D; Shibuya-Takahashi R; Mochizuki M; Fujimori H; Kogure T; Sugai T; Iwai W; Wakui Y; Abue M; Murakami K; Nakamura Y; Yasuda J; Yamaguchi K; Sugamura K; Shibata C; Katayose Y; Satoh K; Tamai K
Cancer Sci; 2021 Nov; 112(11):4580-4592. PubMed ID: 34424582
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein.
Saijoh S; Nakamura-Shima M; Shibuya-Takahashi R; Ito R; Sugawara A; Yamazaki T; Imai T; Asada Y; Matsuura K; Iwai W; Wakui Y; Abue M; Kawamura S; Katayose Y; Fujimori H; Mochizuki M; Yasuda J; Yamaguchi K; Sugamura K; Satoh K; Katori Y; Tamai K
Biochem Biophys Res Commun; 2021 Jan; 537():132-139. PubMed ID: 33412384
[TBL] [Abstract][Full Text] [Related]
3. BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma.
Tamai K; Nakamura-Shima M; Shibuya-Takahashi R; Kanno SI; Yasui A; Mochizuki M; Iwai W; Wakui Y; Abue M; Yamamoto K; Miura K; Mizuma M; Unno M; Kawamura S; Sato I; Yasuda J; Yamaguchi K; Sugamura K; Satoh K
Sci Rep; 2020 Dec; 10(1):21592. PubMed ID: 33299012
[TBL] [Abstract][Full Text] [Related]
4. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
5. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
7. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
8. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Bi L; Ren Y; Feng M; Meng P; Wang Q; Chen W; Jiao Q; Wang Y; Du L; Zhou F; Jiang Y; Chen F; Wang C; Tang B; Wang Y
Cancer Res; 2021 Apr; 81(8):2015-2028. PubMed ID: 33602787
[TBL] [Abstract][Full Text] [Related]
9. Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.
Zou S; Wang C; Liu J; Wang Q; Zhang D; Zhu S; Xu S; Kang M; He S
Mol Cells; 2017 Nov; 40(11):847-854. PubMed ID: 29127951
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.
Lai KP; Chen J; He M; Ching AK; Lau C; Lai PB; To KF; Wong N
Int J Cancer; 2014 Oct; 135(8):1790-9. PubMed ID: 24585547
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
Shen YN; He HG; Shi Y; Cao J; Yuan JY; Wang ZC; Shi CF; Zhu N; Wei YP; Liu F; Huang JL; Yang GS; Lu JH
Mol Carcinog; 2017 Feb; 56(2):751-760. PubMed ID: 27478926
[TBL] [Abstract][Full Text] [Related]
13. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
14. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
15. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
16. High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma.
Wei Y; Wang Y; Gong J; Rao L; Wu Z; Nie T; Shi D; Zhang L
Int J Oncol; 2018 Jan; 52(1):219-230. PubMed ID: 29138811
[TBL] [Abstract][Full Text] [Related]
17. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines.
Cao L; Zhou Y; Zhai B; Liao J; Xu W; Zhang R; Li J; Zhang Y; Chen L; Qian H; Wu M; Yin Z
BMC Gastroenterol; 2011 Jun; 11():71. PubMed ID: 21669008
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
19. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
[TBL] [Abstract][Full Text] [Related]
20. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
